Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICI...(py in Patients with Mucopolysaccharidosi...),Health

#410: Mucopolysaccharidosis Type VI Diagnosis Using Dried Blood Spot Samples - A Brazilian Experience (Gimenes et al)

#413: Craniovertebral Abnormalities and Spinal Cord Compression in Type VI Mucopolysaccharidosis (Horovitz et al)

#423: Decompress Cervical Surgery in Patient with Advanced MPS VI (Solano et al)

#424: Sleep Evaluation in Patients with Mucopolysaccharidosis Type VI (Souza et al)

#426: Severe Cardiomyopathy is Reverted in Patient with Advanced MPS VI Under ERT (Solano et al)

#437: MPS VI - Report of a Very Mild Phenotype in a Brazilian Patient (Souza et al)

#441: High Prevalence of Mental Impairment in a Series of Six Patients with Mucopolysaccharidosis Type VI (Valayannopoulos et al)

#444: Treatment of Diarrhea in Patient with MPS - Cases Report (Frangipani et al)

#449: Phonological Assessment in Patient with MPS I, MPS II and MPS VI (Goncalves et al)

#464: Clinical Characterization and Follow up of 26 Colombian Patients with MPS VI (Solano et al)

#466: Prevalence of MPS VI Patients in Brazil (Martins et al)

#469: Maroteaux Lamy Syndrome: Enzyme Replacement Therapy Outcome in a Severe Form (Ospina et al)

#473: 20-Year Follow Up of Bone Marrow Transplantation in a MPS VI Patient with Substantial Residual Pathology (Andersson)

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulate
'/>"/>